option
Home
Flash News
Content
PatrickSmith
PatrickSmith
February 4, 2026

OpenAI CEO Sam Altman says the company may invest in or subsidize pharmaceutical companies using its AI for drug discovery. This could involve covering AI model usage costs in exchange for royalties on successful new drugs or therapies. While no specific deals are confirmed, the move aims to advance medical research and create a new revenue stream for OpenAI. Altman clarified that standard API users retain full ownership of their R&D outcomes.

Comments (0)
0/300
OR